Amandeep Kaur, MD
Infectious Disease · Bettendorf, IANPI 1619195534
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.5% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 54.0% of the total. Reporting peaked in 2024 at $590 and has fallen 77.1% since, to $135 in 2025.
Across 27 payments — averaging $32.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$472
- Dexcom, Inc.$56
- Merck$50
- UCB, Inc.$38
- Insmed, Inc.$32
- Organon$28
- plus $197 from 10 others
What the payments were for
- Travel & lodging$243%
- Food & beverage$81894%
- Education$324%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $472 |
| Dexcom, Inc. | 2 | $56 |
| Merck | 3 | $50 |
| UCB, Inc. | 1 | $38 |
| Insmed, Inc. | 2 | $32 |
| Organon | 1 | $28 |
| Resmed Corp | 1 | $28 |
| Harmony Biosciences LLC | 1 | $22 |
| Abbott | 1 | $22 |
| Boehringer Ingelheim | 1 | $22 |
| Verona Pharma, Inc. | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Itamar Medical Inc | 1 | $19 |
| Amgen | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Melinta Therapeutics, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$149
How this compares
$875 in reported general payments places this provider in the 80th percentile of 58 infectious disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TivicayDolutegravir Sodium | 13 | $47,915 |
| DescovyEmtricitabine/Tenofov Alafenam | 15 | $30,890 |
| Daptomycin | 79 | $14,561 |
| Cefepime Hcl | 63 | $11,662 |
| ErtapenemErtapenem Sodium | 17 | $11,431 |
| Linezolid | 13 | $4,265 |
| CeftriaxoneCeftriaxone Sodium | 32 | $3,777 |
| Meropenem | 30 | $3,500 |
| Vancomycin Hcl | 23 | $2,443 |
| Voriconazole | 13 | $1,562 |
| Sodium Chloride0.9 % Sodium Chloride | 23 | $1,407 |
| Cefazolin Sodium | 27 | $1,283 |
| Doxycycline Hyclate | 60 | $1,161 |
| Cephalexin | 88 | $1,123 |
| Rifampin | 26 | $1,054 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Bettendorf
- Ravi VemuriDes Moines$16K
- Louis KatzDavenport$12K
- Michael OhlIowa City$9K
- Upinder SinghIowa City$8K
- Karen BrustIowa City$4K
- Patricia WinokurIowa City$3K
- Daniel LampteySioux City$2K
- Ami PatelWaterloo$2K
- Bharat MotwaniDavenport$1K
- Aneesa AfrozeDes Moines$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.